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The past few years have witnessed a renaissance in the
field of immuno-oncology largely due to the clinical suc-
cess in targeting the immune checkpoints CTLA-4 and
PD-1. Towards identification of novel immune check-
point drug targets we developed a dedicated predictive
discovery platform.
The B7/CD28 discovery platform is a predictive model
based on genomic and protein features along with
expression patterns of known B7/CD28 proteins. The
platform has been tested and validated extensively and
has demonstrated its validity by identifying non-novel
immune checkpoints such as TIGIT and VISTA, which
were not used in the design stage.
The B7/CD28 predictive platform was employed to
identify several novel immune checkpoint candidates
which are currently in different validation stages. In this
poster, we will describe our discovery approach as well as
our validation path. In addition, we will present experi-
mental data demonstrating the immuno-modulatory func-
tion and expression patterns of several of our novel
immune checkpoints. These experimental results serve as
an additional confirmation to the accuracy of our B7/
CD28 predictive discovery platform and shed light on the
therapeutic potential of the novel immune checkpoints
identified using this unique discovery approach.
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